Potential asthma treatment worth its salt
An exploratory study by scientists at Singapore's Agency for Science, Technology and Research (A*STAR) into novel solid forms of the anti-inflammatory drug oxaprozin may lead to improvements for the asthma drug, salbutamol, and help reduce inflammation of the airways.

Many drugs, in their original 'parent' form, are not ideal for use in the human body. For example, poor solubility can limit a drugs' ability to disperse in the bloodstream, as is the case for oxaprozin, a widely used anti-inflammatory. Other drugs dissolve too quickly, lose their potency and require multiple doses, such as salbutamol -- a drug used in asthma inhalers to open restricted airways. A solution can be to incorporate two drugs into one solid form to create more effective medications...

https://www.sciencedaily.com/releases/2016/12/161209111924.htm
Like
Comment
Share